PUMA BIOTECHNOLOGY, INC.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $49.2M | $216.6M | $105.1M |
| Jun 2017 | $52.7M | $172.8M | $80.8M |
| Sep 2017 | $102.7M | $181.9M | $79.7M |
| Dec 2017 | $112.2M | $165.5M | $81.7M |
| Mar 2018 | $112.2M | $169.6M | $78.6M |
| Jun 2018 | $189.3M | $227.6M | $95.9M |
| Sep 2018 | $184.8M | $230.7M | $68.3M |
| Dec 2018 | $224.8M | $259.1M | $108.4M |
| Mar 2019 | $287.9M | $331.4M | $48.8M |
| Jun 2019 | $218.1M | $239.9M | $27.2M |
| Sep 2019 | $214.9M | $232.0M | $58.9M |
| Dec 2019 | $217.4M | $234.9M | $60.0M |
| Mar 2020 | $216.2M | $225.5M | $83.4M |
| Jun 2020 | $240.4M | $263.8M | $90.9M |
| Sep 2020 | $262.1M | $261.7M | $90.1M |
| Dec 2020 | $250.2M | $244.2M | $85.3M |
| Mar 2021 | $242.2M | $258.7M | $95.7M |
| Jun 2021 | $230.5M | $260.0M | $89.8M |
| Sep 2021 | $237.2M | $226.3M | $63.9M |
| Dec 2021 | $229.0M | $226.6M | $63.1M |
| Mar 2022 | $193.5M | $200.7M | $63.9M |
| Jun 2022 | $173.9M | $193.7M | $52.8M |
| Sep 2022 | $176.6M | $198.8M | $78.0M |
| Dec 2022 | $200.5M | $222.1M | $76.2M |
| Mar 2023 | $170.4M | $196.3M | $61.4M |
| Jun 2023 | $170.1M | $200.5M | $60.0M |
| Sep 2023 | $164.9M | $203.6M | $81.8M |
| Dec 2023 | $177.1M | $230.5M | $84.6M |
| Mar 2024 | $163.2M | $214.1M | $76.8M |
| Jun 2024 | $156.5M | $205.0M | $67.1M |
| Sep 2024 | $149.6M | $220.7M | $67.3M |
| Dec 2024 | $121.2M | $213.3M | $69.2M |
| Mar 2025 | $99.1M | $196.2M | $63.0M |
| Jun 2025 | $90.2M | $194.9M | $54.7M |
| Sep 2025 | $87.6M | $202.9M | $53.5M |
| Dec 2025 | $86.0M | $216.3M | $29.6M |
| Mar 2026 | $64.3M | $192.7M | $36.2M |
| Jun 2026 | $54.2M | $192.7M | $36.5M |